DiaMedica Therapeutics Inc.

NasdaqCM DMAC

DiaMedica Therapeutics Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

DiaMedica Therapeutics Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

DiaMedica Therapeutics Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -32.11%, a 32.18% change year over year.
DiaMedica Therapeutics Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -47.35%, a 24.68% change year over year.
DiaMedica Therapeutics Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2020 was -62.86%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: DMAC

DiaMedica Therapeutics Inc.

CEO	Mr. Dietrich John Pauls MBA
IPO Date	Aug. 3, 2012
Location	United States
Headquarters	Two Carlson Parkway
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years